Abstracts tagged "Lung Disease"

Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Simone Barsotti^1,2, Chiara Romei³, Elisa Cioffi⁴, Claudia Roncella⁵, Elisabetta Perrone³, Alessandra Tripoli¹, Marta Mosca¹, Fabio Falaschi³ and Rossella Neri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Pisa University Hospital, II Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Pisa University Hospital, I Radiology Unit, Pisa, Italy, ⁶Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…
Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Takahisa Gono¹, Kenichi Masui², Naoshi Nishina³, Shinji Sato⁴ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, Show University Hospital, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…
Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Susanne Graslund^1,2,3, Roman Zubarev⁴, Ingrid E. Lundberg^1,2 and Susanna L. Lundström⁴, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Stockholm, Sweden
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…
Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 400 • 2017 ACR/ARHP Annual Meeting
Combination of the Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation Models As a Model of Interstitial Lung Disease in Rheumatoid Arthritis
Katherine Janike¹, Jill Poole¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell W. Klassen⁴, Amy Nelson⁵, Kristi Warren⁶, Benjamin Swanson⁷ and Ted R. Mikuls⁸, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Int Med/Sec of Rheum/Immun, Univ of NE Medical Ctr, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, University of Nebrasa Medical Center, Omaha, NE, ⁶Department of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including interstitial/inflammatory lung disease (ILD). Whereas the coexistence of RA and ILD is known, mechanisms…
Abstract Number: 568 • 2017 ACR/ARHP Annual Meeting
Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study
Alisson Pugliesi¹, RACHEL ZERBINI MARIANO², Raquel Baldini Campos³, Simone Appenzeller⁴, Manoel Bertolo⁵ and ZORAIDA SACHETTO¹, ¹INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ²Radiology and Diagnostic Imaging, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ³Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), CAMPINAS, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁵INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil
Complement Consumption as a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational StudyBackground/Purpose: Primary Sjögren’s syndrome (pSS) may…
Abstract Number: 838 • 2017 ACR/ARHP Annual Meeting
Rates of New-Onset Pulmonary Disease Among Patients with Systemic Lupus Erythematosus in Sweden
Lindsy J. Forbess¹, Michael Weisman² and Julia F Simard³, ¹Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ³Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Our goal was to examine lung disease and types of pulmonary manifestations observed in patients with SLE. We studied population-based register data from Sweden…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 939 • 2017 ACR/ARHP Annual Meeting
Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients
Louise Malle¹, Dan Yang², Adriana Almeida de Jesus¹, Guibin Chen², Bernadette Marrero¹, Gina A. Montealegre Sanchez¹, Yin Liu³, Gregor Dueckers⁴, Suzanne Ramsey⁵, Joseph Fontana⁶, Rachel VanTries¹, Yan Huang¹, Laisa Santiago⁷, Benito Gonzalez⁸, Paul Brogan⁹, Juergen Brunner¹⁰, Ebun Omoyinmi¹¹, Athimalaipet V. Ramanan¹², Amy Paller¹³, Olcay Y. Jones¹⁴, Seza Ozen¹⁵, Stephen R. Brooks¹⁶, Manfred Boehm¹⁷ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Center for Molecular Medicine, NHLBI/NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS/NIH, Bethesda, MD, ⁴Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁵Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁶Cardiovascular and Pulmonary Branch, NHLBI/NIH, Bethesda, MD, ⁷Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ⁸Luis Calvo Mackenna Hospital, Santiago, Chile, ⁹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹⁰Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, ¹¹University College London Institute of Child Health, London, United Kingdom, ¹²Bristol Royal Hospital for Children, Bristol, United Kingdom, ¹³Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IN, ¹⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁵Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ¹⁷Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD
Background/Purpose: Pulmonary fibrosis, is a life-threatening complication of the monogenic autoinflammatory interferonopathy, STING-Associated Vasculopathy with onset in Infancy (SAVI) that is caused by gain-of-function mutations…
Abstract Number: 1486 • 2017 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Primary Sjögren’s Syndrome : Clinical Presentation, Serological Biomarkers and Long Term Outcome
Chiara Baldini¹, Ilaria Puxeddu², Martina Orlandi³, Francesco Ferro⁴, Elena Elefante⁴, Nicoletta Luciano⁴, Marco Matucci-Cerinic³, Paola Migliorini² and Marta Mosca⁴, ¹Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Allergology and Clinical Immunology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Florence, Florence, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a rare but potentially severe manifestation of primary Sjögren’s syndrome (pSS). The aims of this study were to: 1)…
Abstract Number: 1488 • 2017 ACR/ARHP Annual Meeting
Correlation between Lung Ultrasound, HRCT Findings and Pulmonary Function Tests in Primary Sjögren’s Syndrome (pSS)-Associated Interstitial Lung Disease
Francesco Ferro¹, Alessandra Bulleri², Andrea Delle Sedie¹, Simone Barsotti¹, Nicoletta Luciano¹, Elisa Cioffi³, Elena Elefante¹, Gianfranco Puppo⁴, Marta Mosca¹ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Pneumology Unit, University of Pisa, Pisa, Italy, ⁵Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Recently, pleural irregularity (PI), a new lung ultrasound (US) sign, has been proposed as an emerging tool for the diagnosis of interstitial lung disease…
Abstract Number: 1722 • 2017 ACR/ARHP Annual Meeting
Identification of a Sub-Population of Autoantibodies Targeting BICD2 Cross-Reacting with CENP-a Derived Peptides in Patients with Systemic Sclerosis
Michael Mahler¹, Chelsea Bentow¹, Jay Milo¹, May Choi², Mianbo Wang³, Petra Budde⁴, Murray Baron⁵, Marie Hudson⁶ and Marvin J. Fritzler⁷, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²University of Calgary, Calgary, AB, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Protagen AG, Dortmund, Germany, ⁵Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1756 • 2017 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Distinct or an Incomplete Subset in ANCA Vasculitis Patients?
Simone Barsotti^1,2, Francesco Ferro¹, Elena Elefante¹, Rossella Neri³, Marta Mosca¹ and Chiara Baldini⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, University of Pisa, PISA, Italy, ⁴Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: ANCA-associated vasculitis (AAV) are heterogeneous disorders with a clinical presentation that may range from a full-blown disease to incomplete forms with isolated organ involvement.…
Abstract Number: 2386 • 2017 ACR/ARHP Annual Meeting
The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Ayae Tanaka¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ryutaro Yamazaki², Satoko Arai¹, Takayoshi Owada¹, Reika Maezawa¹ and Masafumi Arima¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects various organs including the lung. The pulmonary involvement is critical for prognosis of the…
Abstract Number: 2566 • 2017 ACR/ARHP Annual Meeting
Myxomavirus-Derived Serpin (Serp-1) Reduces Diffuse Alveolar Hemorrhage in a Murine Model of Lupus
Haoyang Zhuang¹, Shuhong Han¹, Lijun Yang², Sriram Ambadapadi³, Alexandra Lucas⁴ and Westley Reeves⁵, ¹Medicine, University of Florida, Gainesville, FL, ²Pathology, Immunology and laboratory medicine, University of Florida, Gainesville, FL, ³Arizona state University, Tempe, AZ, ⁴Arizona State University, Tempe, AZ, ⁵Rheumatology & Clinical Immology, University of Florida, Gainesville, FL
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an unusual complication of lupus with over 50% mortality. In both humans and mice, DAH is associated with ANCA-negative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].